Skip to main content
TipRanks
Go Ultimate75% OFF

Artivion (AORT) Q3 2026 Earnings Report

400 Followers

AORT Q3 2026 EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.10
One Year Ago EPS
$0.13

AORT Q3 2026 Revenue Results

Actual Revenue
$123.79M
Expected Revenue
$120.97M
Beat/Miss
Beat by +$2.81M
YoY Revenue Growth
+9.17%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
AORT Upcoming Earnings

Artivion's next earnings date is estimated for February 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

AORT Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-27.87%|
Earnings Call Sentiment|Positive

The call was broadly constructive, with solid 9% constant-currency revenue growth, strong stent graft and On-X performance, improving AMDS implant activity, a stronger On-X supply position and continued progress toward the NEXUS and ARTIZEN pipeline milestones. These positives were offset by an 8% adjusted EBITDA decline, gross-margin compression, negative free cash flow, higher leverage, AMDS starter-set ordering challenges, narrowed 2026 guidance and the expected PerClot-related headwinds in 2027.

Company Guidance

For full year 2026, Artivion narrowed its expectation for adjusted constant currency growth to between 8% to 10%, representing a reported revenue range of $484 million to $492 million, with FX expected to have an approximate 1 percentage point tailwind on as-reported revenue; the guidance assumes inconsequential revenue from U.S. NEXUS sales in 2026. Adjusted EBITDA is expected to be in the range of $93 million to $98 million, including approximately $8 million of expense associated with the acquisition of Endospan through 2026. For 2027, the company expects the first meaningful revenue contribution from NEXUS to begin in January 2027, anticipates combined results to be EBITDA neutral for the full year 2027, and expects combined R&D and clinical spending to be in the targeted range of 7% to 8% of sales; completion of the PerClot agreement with Baxter is expected to create a 2 percentage point revenue growth headwind and a 4 percentage point EBITDA growth headwind. In Q4, FX is expected to be at least 1 percentage point headwind.

  • Third-Quarter Revenue GrowthTotal constant-currency revenue increased 9% year over year to $123.8 million in the third quarter of 2026. Excluding PerClot, constant-currency revenue growth was 8%, with PerClot contributing approximately 1 percentage point.
  • Stent Graft GrowthStent graft revenue increased 12% on a constant-currency basis for the second consecutive quarter, despite a tougher AMDS prior-year comparison.
  • AMDS Implant Momentum and Clinical AdoptionU.S. AMDS implants increased, and management said implant activity accelerated following the U.S. PMA approval. The company reported strong clinical results, a short physician learning curve, continued new-account additions and an estimated $150 million annual U.S. market opportunity.
  • NEXUS Launch PreparationPreparations for the anticipated January 2027 U.S. NEXUS launch are progressing, including manufacturing-capacity expansion, inventory building, value analysis committee work, U.S. sales-team expansion and surgeon training. The first surgeon training event is planned for December, and management reported excellent surgeon feedback and significant demand ahead of launch.
  • On-X Revenue and Supply PositionOn-X revenue grew 13% year over year on a constant-currency basis, driven by continued mid-teens growth in the U.S. Management said the company exited the quarter in its strongest On-X supply position in several years following investments in the Austin manufacturing facility.
  • Tissue Processing Ahead of ExpectationsTissue processing revenue declined 0.3% year over year on a constant-currency basis because of a difficult prior-year comparison, but performance was ahead of management's expectations for the quarter.
  • PerClot-Driven Other Revenue GrowthRevenue in the other category increased 93% year over year, driven by PerClot. Management described the PerClot transaction as a significant positive because it converted a nonstrategic asset into cash.
  • ARTIZEN Trial ProgressThe ARTIZEN clinical trial for ARCEVO LSA had enrolled 56 patients in a planned nonrandomized trial of up to 132 patients across the U.S. and Europe and up to 30 centers. Enrollment is expected to be completed in mid-2027, and the first 30 patients are scheduled to be presented at the AATS Aortic Symposium on November 19, 2026.
  • Future Pipeline Market OpportunitiesManagement identified four U.S. aortic growth platforms representing approximately $430 million of current market opportunity: AMDS at an estimated $150 million, On-X at $100 million, NEXUS at $100 million and ARTIZEN at $80 million. Assuming ARTIZEN meets its endpoints and receives FDA approval, approval is anticipated in 2029.
  • Broad Regional Revenue GrowthThird-quarter revenue increased 8% in North America, 11% in EMEA, 8% in Asia Pacific and 5% in Latin America compared with the third quarter of 2025.
  • Operating Expense LeverageNon-GAAP general, administrative and marketing expenses were 46.6% of sales versus 47.3% in the prior-year quarter, an approximately 120-basis-point improvement from leveraging existing infrastructure, partially offset by higher amortization following the Endospan acquisition.
  • Expected Gross-Margin Improvement in Q4Management expects fourth-quarter gross margin to be more in line with the full-year average, supported by nonrecurrence of period costs and the beginning of volume ramp in the On-X and NEXUS facilities.
  • 2027 NEXUS Revenue Ramp and EBITDA NeutralityManagement expects the first meaningful NEXUS revenue contribution to begin in January 2027. Combined results are expected to be EBITDA neutral for the full year 2027 as U.S. NEXUS revenue ramps and combined R&D and clinical spending is aligned to a targeted 7% to 8% of sales.
  • BioGlue Outlook MaintainedBioGlue revenue increased 0.1% year over year on a constant-currency basis. Management said the product line's long-term outlook remains unchanged despite normal quarter-to-quarter variability from stocking distributor orders.

AORT Earnings History

AORT earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 18, 20272026 (Q4)-0.04-0.05――
Nov 05, 20262026 (Q3)-0.06-0.160.13-223.08% (-0.29)
Aug 06, 20262026 (Q2)0.00-0.280.03-1033.33% (-0.31)
May 07, 20262026 (Q1)0.030.03-0.01400.00% (+0.04)
Feb 12, 20262025 (Q4)0.060.05-0.39112.82% (+0.44)
Nov 06, 20252025 (Q3)0.020.13-0.05360.00% (+0.18)
Aug 07, 20252025 (Q2)-0.000.03-0.05160.00% (+0.08)
May 05, 20252025 (Q1)-0.12-0.010.18-105.56% (-0.19)
Feb 24, 20252024 (Q4)-0.07-0.39-0.1-290.00% (-0.29)
Nov 07, 20242024 (Q3)-0.06-0.05-0.2479.17% (+0.19)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed